Prediction Market for Clinical Trials

Current Markets

ABS-201 is an anti-PRLR antibody in AGA; this market requires numerical TAHC improvement, not safety/PK alone, by Dec.

Sonelokimab is being tested in biologic-naive psoriatic arthritis; this market resolves on Week 16 ACR50 success by Sept.

GPS is being tested as AML maintenance therapy; this market resolves on statistically significant overall survival success by Nov.

Trial	Company	Yes	No	Catalyst
ABS-201 in Androgenetic Alopecia ABS-201 is an anti-PRLR antibody in AGA; this market requires numerical TAHC improvement, not safety/PK alone, by Dec.	Absci	48%	52%	Jun 8Interim DataPhase 1
Sonelokimab in Psoriatic Arthritis Sonelokimab is being tested in biologic-naive psoriatic arthritis; this market resolves on Week 16 ACR50 success by Sept.	MoonLake Immunotherapeutics	80%	20%	Mar 28ResultsPhase 3
GPS Maintenance Therapy in AML Remission GPS is being tested as AML maintenance therapy; this market resolves on statistically significant overall survival success by Nov.	SELLAS Life Sciences Group	0%	100%	Nov 30Expected catalystClinicalTrials.govPhase 3